peptides for fertility FAQ

We can help with PCOS. Peptides can balance insulin. Diet changes help too. We treat the root cause of PCOS.

Do not use peptides with visible aggregates. They've undergone irreversible denaturation and lost bioactivity even if HPLC still shows parent compound peak. The likely cause: alcohol-containing bacteriostatic water denatures peptides at the air-liquid interface, or hydrophobic peptide regions collapsed due to hypotonic diluent. Prevent recurrence by reconstituting in PBS or 0.1% BSA solution, storing at 2–8°C in the dark, and limiting freeze-thaw cycles to two maximum. If multi-dose vials are required, aliquot immediately after reconstitution into single-use volumes to eliminate repeated puncture and air exposure.

This is expected pharmacology, not experimental error. GnRH analogs produce biphasic responses: initial 48–72 hour flare (supraphysiological LH/FSH) followed by profound suppression as continuous receptor occupancy downregulates pituitary GnRH receptors by 80–90%. If your study requires sustained stimulation, switch to pulsatile native GnRH administered every 90 minutes via programmable pump. This replicates physiological signaling and avoids desensitization. Alternatively, use Kisspeptin-10 for upstream activation that preserves endogenous pulse generation.

Verify peptide purity exceeds 98% by HPLC and request mass spectrometry confirmation of intact molecular weight. Deletion sequences missing even one amino acid reduce GPR54 binding affinity by 60–80%. If purity is confirmed, check reconstitution pH: solutions below 6.5 protonate histidine residues critical for receptor binding, reducing agonist potency by half. Switch to phosphate-buffered saline (pH 7.4) as diluent and pre-warm vials to room temperature before injection. Cold peptide solutions precipitate at the injection site, creating depot effect that delays absorption and flattens peak LH response.

You risk worsening insulin resistance and disrupting glucose metabolism. Both of which impair ovarian function more than they help. Growth hormone and IGF-1 elevation increases hepatic glucose output and reduces peripheral insulin sensitivity. In women with PCOS or metabolic syndrome, this compounds the hyperinsulinemia that already suppresses SHBG (sex hormone-binding globulin) and elevates free androgens, worsening anovulation. The research showing GH benefit in IVF poor responders specifically selected patients with low baseline IGF-1. Applying the same protocol to metabolically normal women produces harm, not benefit.

Coordinate with your reproductive endocrinologist before adding any peptide. Most peptides for fertility interact with the hormone protocols IVF cycles depend on. GnRH agonists and antagonists are already part of standard IVF stimulation. Adding exogenous kisspeptin or other GnRH-modulating peptides disrupts the controlled hormone timing the protocol requires. Growth hormone co-treatment during IVF is studied and sometimes prescribed, but dosing and timing are protocol-specific. Self-administering peptides during an IVF cycle without medical coordination risks cycle failure or ovarian hyperstimulation.

Thymic peptides have no documented mechanism to improve fertility in immunologically normal individuals. The Th1/Th2 cytokine modulation they produce is therapeutic when the immune system is attacking the pregnancy (antiphospholipid syndrome, lupus, elevated NK cells). But irrelevant when immune function is normal. Using thymic peptides without confirming an immune etiology through antiphospholipid antibody panels, ANA testing, or endometrial NK cell biopsy is pharmacologically unfounded. The intervention requires a diagnosis first.

Do not use it until you confirm with the supplier what the solvent is and whether reconstitution was performed under sterile conditions. Pre-dissolved peptides have significantly shorter shelf lives than lyophilized forms. Aqueous solutions promote hydrolysis of peptide bonds, especially at positions adjacent to aspartic acid and asparagine residues. GnRH analogs in solution at pH 7.4 lose approximately 15% activity per month even when refrigerated at 2–8°C. If the supplier reconstituted the peptide without your request, that suggests batch handling inconsistencies that could affect other quality parameters.

Verify receptor expression in your cell line or tissue model first. If the target cells don't express KISS1R, exogenous kisspeptin won't produce a response regardless of dose. Next, confirm the peptide is reaching the target compartment: peptides >3 kDa don't cross cell membranes efficiently, so if you're studying an intracellular target, you need cell-penetrating peptide (CPP) conjugation or electroporation. Finally, check whether your readout is downstream enough. GnRH stimulates LH secretion within 30 minutes, but downstream effects like steroidogenesis take 4–6 hours. Measuring too early or too late in the signaling cascade produces false negatives.

Check whether the certificate of analysis included sequence verification by mass spectrometry. HPLC purity measures the percentage of total protein that elutes as a single peak, not whether that peak is the correct sequence. A synthesis error at position 3 (wrong amino acid incorporated) will still show 98% purity if the byproducts were removed, but the peptide will have zero bioactivity. The next diagnostic step is circular dichroism spectroscopy to confirm secondary structure, especially for peptides with required alpha-helical or beta-sheet domains. Alternatively, run a positive control using a peptide from a different supplier. If that works, the issue is the compound, not your protocol.

Aliquot the reconstituted solution into single-use volumes and store at −80°C in low-protein-binding tubes. Avoid repeated freeze-thaw cycles. Each cycle causes ice crystal formation that shears peptide chains and denatures tertiary structure. Add a cryoprotectant like trehalose (10–20% w/v) or glycerol (5–10% v/v) to the reconstituted solution before freezing. These compounds prevent ice crystal growth and stabilize peptide conformation. Even with cryoprotectants, expect 5–10% activity loss per month at −80°C for most fertility peptides. If your experimental timeline requires longer storage, order lyophilized aliquots and reconstitute fresh for each experiment.

Verify GPR54 receptor expression in your target tissue first. Not all animal models express Kiss1R at equivalent density to humans. In rodent models, kisspeptin-10 requires 10–100× higher doses (per kg) than in primates to achieve comparable LH response, likely due to differences in receptor affinity and hypothalamic Kiss1 neuron density. If dosing into the expected range produces no response, consider switching to a longer kisspeptin analog (kisspeptin-54) or adding an NK3 receptor agonist to amplify the signal at the KNDy neuron level.

Pretreat with a GnRH antagonist (cetrorelix 0.25 mg/day SC) for 48 hours to suppress endogenous LH pulsatility, then administer exogenous recombinant FSH or FSH-beta fragments at your target dose. The antagonist blocks pituitary LH release without affecting peripheral FSH receptor signaling. This is the standard approach in IVF research when isolating follicular development from androgen synthesis. Monitor LH levels at 24-hour intervals; if suppression isn't complete (LH >1 IU/L), increase antagonist dose to 0.5 mg/day.

Discard it immediately. Cloudiness or visible particulate indicates protein aggregation or contamination, both of which compromise bioactivity and introduce experimental variability you can't control. Aggregated peptides may retain partial receptor binding but with altered pharmacokinetics that make dose-response curves unreliable. Prevention: reconstitute with bacteriostatic water (not sterile saline, which lacks preservatives), use within the specified timeframe (7 days for most fertility peptides), and avoid freeze-thaw cycles entirely. Aliquot into single-use vials at reconstitution if you need multiple doses.

No. If baseline IGF-1 is above 200 ng/mL and FSH is within normal range, adding growth hormone secretagogues creates supraphysiological GH spikes without proportional reproductive benefit. The mechanism relies on correcting a deficiency. Not maximising an already-sufficient pathway. Elevated GH without corresponding need increases insulin resistance risk and can suppress thyroid function through negative feedback on TSH.

For growth hormone secretagogues with 24-hour half-lives like MK 677, missing three doses means plasma levels drop below therapeutic threshold. Resume dosing immediately at the standard dose. Do not double-dose to 'catch up.' The GH pulse amplification effect resets within 48 hours of resuming consistent administration. For shorter half-life peptides like CJC-1295/Ipamorelin, missing three doses has minimal impact on overall cycle effectiveness as long as the total cycle duration (8–12 weeks) is maintained.

These are dose-dependent side effects caused by fluid retention from elevated GH. Reduce dose by 30–40% immediately and reassess after one week. If symptoms persist at reduced dose, discontinue and evaluate whether IGF-1 elevation is occurring faster than expected. Some individuals are hyperresponders and require lower-than-typical dosing. Joint pain on GH secretagogues is not a sign of effectiveness; it's a sign of excessive dosing relative to your physiology.

Pulsatile gonadorelin therapy is the mechanistically appropriate next step. Clomiphene works by blocking estrogen receptors in the hypothalamus, which removes negative feedback and increases GnRH release. But this only works if your hypothalamus is capable of producing GnRH in the first place. In hypothalamic amenorrhea (HA), GnRH neuron firing is suppressed by chronic stress, low body fat, or excessive exercise. Gonadorelin bypasses the hypothalamus entirely by delivering exogenous GnRH in the pulsatile pattern required for normal pituitary function. Clinical protocols use subcutaneous pumps delivering 5–10mcg every 90 minutes, restoring ovulation in 80% of HA cases.

Recurrent implantation failure with morphologically normal embryos suggests an immune tolerance problem, not an embryo quality problem. Thymosin alpha-1 at 1.6mg subcutaneous twice weekly starting two weeks before transfer has shown 42% clinical pregnancy rates versus 22% in untreated controls in women with RIF. The mechanism is T-regulatory cell upregulation. These Tregs suppress NK cell cytotoxicity against the implanting embryo. Before starting thymosin alpha-1, request peripheral NK cell percentage testing (CD56+ cells) and endometrial biopsy for immune profiling if available. Elevated uterine NK cells (>5% of stromal cells) correlate with poor implantation even when peripheral levels are normal.

Kisspeptin-10 triggers ovulation with comparable LH surge timing to hCG but with significantly lower OHSS (ovarian hyperstimulation syndrome) risk. hCG has a half-life of 24–36 hours, providing sustained luteotropic support but also prolonging the risk window for OHSS in high responders. Kisspeptin-10's 28-minute half-life produces a sharp, physiological LH surge without the prolonged stimulation. A Phase 2 trial published in JCEM documented zero OHSS cases in the kisspeptin-10 arm versus 4% in the hCG arm among women with >18 follicles. The limitation is that kisspeptin-10 requires exogenous luteal phase support (progesterone supplementation), whereas hCG provides intrinsic corpus luteum support.